Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Cardiovascular Imaging Reports
Erschienen in: Current Cardiovascular Imaging Reports 4/2012

01.08.2012 | Intravascular Imaging (U Landmesser, Section Editor)

Intracoronary IVUS for Evaluation of Atherosclerosis Progression

verfasst von: Kiyoko Uno, Yu Kataoka, Rishi Puri, Stephen J. Nicholls

Erschienen in: Current Cardiovascular Imaging Reports | Ausgabe 4/2012

Einloggen, um Zugang zu erhalten

Abstract

Serial imaging of the coronary arteries with intravascular ultrasound (IVUS) enables monitoring progression of atherosclerotic plaque and characterization of the clinical and pharmacological factors that influence it. These studies have demonstrated the importance of targeting the major cardiovascular risk factors, with evidence of slowing progression and in some cases promoting disease regression. In addition, technological advances in intravascular imaging also permit characterization of individual plaque components, enabling more comprehensive evaluation of anti-atherosclerotic therapies.
Literatur
1.
Nissen SE, Tuzcu EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292(18):2217–25.PubMedCrossRef
2.
Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290(17):2292–300.PubMedCrossRef
3.
Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006;295(13):1556–65.PubMedCrossRef
4.
Mintz GS, Nissen SE, Anderson WD, et al. American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol Apr. 2001;37(5):1478–92.CrossRef
5.
Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol. 2000;20(5):1262–75.PubMedCrossRef
6.
Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–95.PubMedCrossRef
7.
Nicholls SJ, Sipahi I, Schoenhagen P, Crowe T, Tuzcu EM, Nissen SE. Application of intravascular ultrasound in anti-atherosclerotic drug development. Nat Rev Drug Discov. 2006;5(6):485–92.PubMedCrossRef
8.
•• Nicholls SJ, Hsu A, Wolski K, et al. Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol. 2010;55:2399–407. First demonstration of relationship between the extent and progression of coronary atherosclerosis, as determined by IVUS, and the prospective risk for cardiovascular events.PubMedCrossRef
9.
Cliff WJ, Heathcote CR, Moss NS, Reichenbach DD. The coronary arteries in cases of cardiac and noncardiac sudden death. Am J Pathol. 1988;132(2):319–29.PubMed
10.
Furberg CD, Adams HPJ, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovasular event. Asymptomatic Carotid Artery Progression Study (ACAPS) Researh Group. Circulation. 1994;90(4):1679087.CrossRef
11.
Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323(19):1289–98.PubMedCrossRef
12.
Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004;291(9):1071–80.PubMedCrossRef
13.
Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352(1):29–38.PubMedCrossRef
14.
Ballantyne CM, Raichlen JS, Nicholls SJ, et al. Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography: a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden. Circulation. 2008;117(19):2458–66.PubMedCrossRef
15.
Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, High-Density Lipoprotein Cholesterol, and Regression of Coronary Atherosclerosis. JAMA. 2007;297(5):499–508.PubMedCrossRef
16.
Nicholls SJ, Ballantyne CM, Barter PJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078–87.PubMedCrossRef
17.
Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrone: demonstration of the beneficial on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event: the ESTABLISH study. Circulation. 2004;110(9):1061–8.PubMedCrossRef
18.
Jensen LO, Thayssen P, Pedersen KE, et al. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation. 2004;110(3):265–70.PubMedCrossRef
19.
• Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. The New England journal of medicine. 2007;357(13):1301–1310. This paper showed the importance of a low HD-C in patients with very low levels of LDL-C.PubMedCrossRef
20.
Nicholls SJ, Cutri B, Worthley SG, et al. Impact of short-term administration of high-density lipoproteins and atorvastatin on atherosclerosis in rabbits. Arterioscler Thromb Vasc Biol. 2005;25(11):2416–21.PubMedCrossRef
21.
Gordon DJ, Rifkind BM. High-density lipoprotein-the clinical implications of recent studies. N Engl J Med. 1989;321(19):1311–6.PubMedCrossRef
22.
Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest. 1990;85(4):1234–41.PubMedCrossRef
23.
Zannis VI, Chroni A, Krieger M. Role of apoA-I, ABCA1, LCAT, and SR-B1 in the biogenesis of HDL. J Mol Med (Berl). 2006;84(4):276–94.CrossRef
24.
Barter P, Nicholls SJ, Rye KA, et al. Antiinflammatory properties of HDL. Circ Res. 2004;95(8):764–72.PubMedCrossRef
25.
Nicholls SJ, Tuzcu EM, Sipahi I, et al. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol. 2006;47(5):992–7.PubMedCrossRef
26.
Waksman R, Torguson R, Kent KM, et al. A first-in-man, randomized, placebo-controlles study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acure coronary syndrome. J Am Coll Cardiol. 2010;55(24):2727–35.PubMedCrossRef
27.
Barter PJ, Chapman MJ, Hennekens CH, et al. Cholesteryl ester transfer protein. A novel target for raising HDL and inhibiting atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology. 2003;23:160–7.PubMedCrossRef
28.
Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357(21):2109–22.PubMedCrossRef
29.
Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med. 2007;356(13):1304–16.PubMedCrossRef
30.
Nicholls SJ, Tuzcu EM, Brennan DM, et al. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation). Circulation. 2008;118(24):2506–14.PubMedCrossRef
31.
Cannon CP, Shah S, Dansky HM, et al. Determining the Efficacy and Tolerability Investigators. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med. 2010;363(35):2406–15.PubMedCrossRef
32.
Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA. 2011;306(19):2099–109.PubMedCrossRef
33.
Fayad ZA, Mani V, Woodward M, et al. dal-PLAQUE Investigators. Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imagin (dal-PLAQUE): a randomised clinical trial. Lancet. 2011;378(9802):1547–59.PubMedCrossRef
34.
35.
Bailey D, Jahagirdar R, Gordon A, et al. RVX-208: a small molecule that increases apolipoprotein A-I and high-density lipoprotein cholesterol in vitro and in vivo. J Am Coll Cardiol. 2010;55(23):2580–9.PubMedCrossRef
36.
van der Steeg WA, Holme L, Boekholdt SM, et al. High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol. 2008;51(6):634–42.PubMedCrossRef
37.
Brener SJ, Ivanc TB, Poliszczuk R, et al. Antihypertensive therapy and regression of coronary artery disease: Insights from the Comparison of Amlodipine versus Enalapril to Limit Occurences of Thrombosis (CAMELOT) and Norvasc for Regression of Manifest Atherosclerotic Lesions by Intravascular Sonographic Evaluation (NORMALISE) trials. Am Heart J. 2006;152:1059–63.PubMedCrossRef
38.
Sipahi I, Tuzcu EM, Schoenhagen P, et al. Effects of Normal, Pre-Hypertensive, and Hypertensive Blood Pressure Levels on Progression of Coronary Atherosclerosis. J Am Coll Cardiol. 2006;48:833–8.PubMedCrossRef
39.
Lϋscher TF, Pieper M, Tendera M, et al. A randomized placebo-controlled study on the effect of nifedipine on coronary endothelial function and plaque formation in patients with coronary artery disease: the ENCORE II study. Eur Heart J. 2009;30(13):1590–7.CrossRef
40.
Chhatriwalla AK, Nicholls SJ, Wang TH, et al. Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. J Am Coll Cardiol. 2009;53(13):1110–5.PubMedCrossRef
41.
Nicholls SJ, Tuzcu EM, Crowe T, et al. Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. J Am Coll Cardiol. 2006;47(10):1967–75.PubMedCrossRef
42.
Nissen SE, Nicholls SJ, Wolski K, et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008;299(13):1561–73.PubMedCrossRef
43.
Nicholls SJ, Tuzcu EM, Wolski K, et al. Lowering the triglyceride/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) study. J Am Coll Cardiol. 2011;57(2):153–9.PubMedCrossRef
44.
Kataoka Y, Shao M, Wolski K, et al. Multiple risk factor intervention and progression of coronary atherosclerosis in patients with type 2 diabetes mellitus. Eur J Prev Cardiolog. 2012.
45.
Yamagishi M, Terashima M, Awano K, et al. Morphology of vulnerable coronary plaque: insights from follow-up of patients examined by intravascular ultrasound before an acute coronary syndrome. J Am Coll Cardiol. 2000;35(1):106–11.PubMedCrossRef
46.
Ehara S, Kobayashi Y, Yoshiyama M, et al. Coronary artery calcification revisited. J Atheroscler Thromb. 2006;13(1):31–7.PubMedCrossRef
47.
Schoenhagen P, Ziada KM, Kapadia SR, et al. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation. 2000;101(6):598–603.PubMedCrossRef
48.
Nair A, Kuban BD, Obuchowski N, Vince DG. Assessing spectral algorithms to predict atherosclerotic plaque composition with normalized and raw intravascular ultrasound data. Ultrasound Med Biol. 2001;27(10):1319–31.PubMedCrossRef
49.
Nasu K, Tsuchikane E, Katoh O, et al. Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology compared with in vitro histopathology. J Am Coll Cardiol. 2006;47(12):2405–12.PubMedCrossRef
50.
Hong MK, Mintz GS, Lee CW, et al. A three-vessel virtual histology intravascular ultrasound analysis of frequency and distribution of thin-cap fibroatheromas in patients with acute coronary syndrome or stable angina pectoris. Am J Cardiol. 2008;101(5):568–72.PubMedCrossRef
51.
Shin ES, Garcia-Garcia HM, Okamura T, Serruys PW. Effect of statins on coronary bifurcation atherosclerosis: an intravascular ultrasound virtual histology study. The international journal of cardiovascular imaging. 2011;[Epub ahead of print].
52.
Hong MK, Park DW, Lee CW, et al. Effects of statin treatments on coronary plaques assessed by volumetric virtual histology intravascular ultrasound analysis. JACC Cardiovasc Intv. 2009;2(7):679–88.CrossRef
53.
Hattori K, Ozaki K, Ismail TF, et al. Impact of Statin Therapy on Plaque Characteristics as Assessed by Serial OCT, Grayscale and Integrated Backscatter-IVUS. Jacc. 2012;5(2):169–77.PubMed
54.
• Stone GW, Maehara A, Lansky AJ, et al. A prospective natural-history study of coronary atherosclerosis. The New England journal of medicine. Jan 20;364(3):226–235. This report showed that the recurrent major events in acute coronary syndrome patients were associated with nonculprit lesions with large plaque burden and thin-cap fibroatheromas, as determined by grayscale IVUS and radiofrequency IVUS.
55.
Thim T, Hagensen MK, Wallace-Bradley D, et al. Unreliable assessment of necrotic core by virtual histology intravascular ultrasound in porcine coronary artery disease. Circ Cardiovasc Imaging. Jul;3(4):384–391.
56.
Huang D, Swanson EA, Lin CP, et al. Optical coherence tomography. Science New York, NY. 1991;254(5035):1178–81.PubMedCrossRef
57.
Yabushita H, Bouma BE, Houser SL, et al. Characterization of human atherosclerosis by optical coherence tomography. Circulation. 2002;106(13):1640–5.PubMedCrossRef
58.
Kume T, Akasaka T, Kawamoto T, et al. Measurement of the thickness of the fibrous cap by optical coherence tomography. Am Heart J. 2006;152(4):755 e751–754.CrossRef
59.
Uemura S, Ishigami KI, Soeda T, et al. Thin-cap fibroatheroma and microchannel findings in optical coherence tomography correlate with subsequent progression of coronary atheromatous plaques. Eur Heart J. Aug 10.
60.
Fujii K, Kawasaki D, Masutani M, et al. OCT assessment of thin-cap fibroatheroma distribution in native coronary arteries. Jacc. Feb;3(2):168–175.
61.
Thieme T, Wernecke KD, Meyer R, et al. Angioscopic evaluation of atherosclerotic plaques: validation by histomorphologic analysis and association with stable and unstable coronary syndromes. J Am Coll Cardiol. 1996;28(1):1–6.PubMedCrossRef
62.
Ishibashi F, Aziz K, Abela GS, Waxman S. Update on coronary angioscopy: review of a 20-year experience and potential application for detection of vulnerable plaque. J Interv Cardiol. 2006;19(1):17–25.PubMedCrossRef
63.
Miyamoto A, Prieto AR, Friedl SE, et al. Atheromatous plaque cap thickness can be determined by quantitative color analysis during angioscopy: implications for identifying the vulnerable plaque. Clin Cardiol. 2004;27(1):9–15.PubMedCrossRef
64.
Mizuno K, Satomura K, Miyamoto A, et al. Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med. 1992;326(5):287–91.PubMedCrossRef
65.
Alfonso F, Segovia J, Goicolea J, et al. Angioscopic characteristics of coronary narrowing in patients with recurrent myocardial ischemia after myocardial infarction. Am J Cardiol. 1997;79(10):1394–6.PubMedCrossRef
66.
Takano M, Mizuno K, Yokoyama S, et al. Changes in coronary plaque color and morphology by lipid-lowering therapy with atorvastatin: serial evaluation by coronary angioscopy. J Am Coll Cardiol. 2003;42(4):680–6.PubMedCrossRef
67.
Frangioni JV. In vivo near-infrared fluorescence imaging. Curr Opin Chem Biol. 2003;7(5):626–34.PubMedCrossRef
68.
Caplan JD, Waxman S, Nesto RW, Muller JE. Near-infrared spectroscopy for the detection of vulnerable coronary artery plaques. J Am Coll Cardiol. 2006;47(8 Suppl):C92–6.PubMedCrossRef
69.
Tardif JC, Grégoire J, L'Allier PL, et al. Avasimibe and Progression of Lesions on UltraSound (A-PLUS) Investigators. Effects of the acyl coenzyme A: cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation. 2004;110(21):3372–7.PubMedCrossRef
70.
Nissen SE, Tuzcu EM, Brewer HB, et al. ACAT Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Investigators. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N Engl J Med. 2006;354(12):1253–63.PubMedCrossRef
71.
Tardif JC, Grégoire J, L'Allier PL, et al. Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis. JAMA. 2007;297(15):1675–82.PubMedCrossRef
72.
Nissen SE, Nicholls SJ, Wolski K, et al. STRADIVARIUS Investigators. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA. 2008;299(13):1547–60.PubMedCrossRef
Metadaten
Titel
Intracoronary IVUS for Evaluation of Atherosclerosis Progression
verfasst von
Kiyoko Uno
Yu Kataoka
Rishi Puri
Stephen J. Nicholls
Publikationsdatum
01.08.2012
Verlag
Current Science Inc.
Erschienen in
Current Cardiovascular Imaging Reports / Ausgabe 4/2012
Print ISSN: 1941-9066
Elektronische ISSN: 1941-9074
DOI
https://doi.org/10.1007/s12410-012-9141-9

Weitere Artikel der Ausgabe 4/2012

Current Cardiovascular Imaging Reports 4/2012 Zur Ausgabe

Invited Commentary

Clinical Applications of Cardiac Magnetic Resonance Spectroscopy (CMRS)

Intravascular Imaging (U Landmesser, Section Editor)

Optical Coherence Tomography: Potential Clinical Applications

Intravascular Imaging (U Landmesser, Section Editor)

How Do OCT and IVUS Compare to Histology in Coronary Atherosclerosis and Stenting?

Intravascular Imaging (U Landmesser, Section Editor)

Three-Dimensional Fourier-Domain Optical Coherence Tomography Imaging: Advantages and Future Development

Intravascular Imaging (U Landmesser, Section Editor)

Optical Coherence Tomography Imaging: Novel Insights into the Vascular Response After Coronary Stent Implantation

Invited Commentary

Molecular Imaging of Selectins in Endothelial Activation

Neu im Fachgebiet Kardiologie

Schadet Ärger den Gefäßen?

14.05.2024 Arteriosklerose Nachrichten

In einer Studie aus New York wirkte sich Ärger kurzfristig deutlich negativ auf die Endothelfunktion gesunder Probanden aus. Möglicherweise hat dies Einfluss auf die kardiovaskuläre Gesundheit.

Intervallfasten zur Regeneration des Herzmuskels?

14.05.2024 Herzinfarkt Nachrichten

Die Nahrungsaufnahme auf wenige Stunden am Tag zu beschränken, hat möglicherweise einen günstigen Einfluss auf die Prognose nach akutem ST-Hebungsinfarkt. Darauf deutet eine Studie an der Uniklinik in Halle an der Saale hin.

Shunt-Therapie bei Herzinsuffizienz: Kein Anzug, der allen passt

13.05.2024 Chronische Herzinsuffizienz Nachrichten

Die Anlage eines interatrialen Shunts zur Reduktion des linksatrialen Drucks ist ein neuer Therapieansatz bei Herzinsuffizienz. Viele Patienten sprechen darauf an, andere jedoch nicht. 

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise